Home-based Respiratory Training After Stroke
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02400138 |
Recruitment Status :
Completed
First Posted : March 26, 2015
Last Update Posted : October 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke | Other: Respiratory training Other: Control | Not Applicable |
Rationale: Weakness of the respiratory muscles demonstrated by individuals with stroke, may generate important symptoms, such as fatigue and dyspnea. Since adequate strength of the inspiratory and expiratory muscles is required, mainly when performing physical activities, rehabilitation interventions for stroke subjects should include respiratory training.
Aim: This study will test the hypothesis that home-based combined inspiratory muscular training (IMT) plus expiratory muscular training (EMT) program is effective in improving strength of the inspiratory and expiratory muscles, endurance of the inspiratory muscles, dyspnea, walking capacity, and ocurrence of respiratory complications after stroke.
Design: For this prospective, double-blinded, randomized clinical trial, people after stroke will be randomly allocated into either experimental or control/sham groups. The experimental group will undertake training of the inspiratory plus expiratory muscles with the Orygen Dual Valve, regulated at 50% of the subjects' maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values, seven times/week over eight weeks during 40 minutes/day. The control group will undertake the same protocol, but the participants will receive the devices without resistance. At baseline, post intervention, and four weeks after the cessation of the intervention, researchers blinded to group allocations will collect all outcome measures.
Study outcomes: Primary outcomes will be MIP. Secondary outcomes will include MEP, inspiratory endurance, dyspnea, walking capacity, and ocurrence of respiratory complications.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Home-based Respiratory Training After Stroke: A Randomized Controlled Trial |
Actual Study Start Date : | February 2016 |
Actual Primary Completion Date : | June 30, 2017 |
Actual Study Completion Date : | July 15, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Respiratory training
Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
|
Other: Respiratory training
Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values. |
Sham Comparator: Control
The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
|
Other: Control
The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring. |
- Maximal inspiratory pressure [ Time Frame: Baseline (week 0), after training (week 8) and one-month follow-up (weeks 12) ]Changes in maximal inspiratory pressures will be assessed by a digital manovacuometer, following previously described protocols.
- Maximal expiratory pressure [ Time Frame: Baseline (week 0), after training (week 8) and one-month follow-up (weeks 12) ]Changes in maximal expiratory pressures will be assessed by a digital manovacuometer, following previously described protocols.
- Inspiratory endurance [ Time Frame: Baseline (week 0), after training (week 8) and one-month follow-up (weeks 12) ]Changes in inspiratory endurance will be assessed by the powerbreathe device, following previously described protocols.
- Dyspnea [ Time Frame: Baseline (week 0), after training (week 8) and one-month follow-up (weeks 12) ]Changes in dyspnea will be assessed by the Medical Research Council Scale.
- Ocurrence of respiratory complications [ Time Frame: Baseline (week 0), after training (week 8) and one-month follow-up (weeks 12) ]Changes in ocurrence of respiratory complications will be assessed by asking the participants, whether and how often they were admitted to a hospital, due to respiratory reasons.
- Walking capacity [ Time Frame: Baseline (week 0), after training (week 8) and one-month follow-up (weeks 12) ]Changes in walking capacity will be evaluated by the six-minute walking test

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Stroke survivors will be eligible if they: were >3 months and <5 years after their last episode of stroke; were >20 years of age; their maximal inspiratory pressure was <80 cmH2O or maximal expiratory pressure was <90 cmH2O [18]; were not undertaking any respiratory training; and were able to provide informed consent.
Exclusion Criteria:
Subjects will be excluded if they had cognitive deficits, facial palsy, associated respiratory diseases, or unstable conditions which might prevent measurement or training; or undergone thoracic or abdominal surgery.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02400138
Brazil | |
Department of Physical Therapy, Universidade Federal de Minas Gerais | |
Belo Horizonte, MG, Brazil, 31270-901 | |
NeuroGroup Laboratory | |
Belo Horizonte, MG, Brazil, 31270-901 |
Study Director: | Fatima Rodrigues-de-Paula, Ph.D. | Federal University of Minas Gerais |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Luci Fuscaldi Teixeira-Salmela, Titular professor, Federal University of Minas Gerais |
ClinicalTrials.gov Identifier: | NCT02400138 |
Other Study ID Numbers: |
RTS-01 |
First Posted: | March 26, 2015 Key Record Dates |
Last Update Posted: | October 26, 2017 |
Last Verified: | October 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |